한국임상약학회지 (Korean Journal of Clinical Pharmacy)

  • 제20권1호
  • /
  • Pages.66-71
  • /
  • 2010
  • /
  • 1226-6051(pISSN)
  • /
  • 2508-786X(eISSN)
한국임상약학회 (Korean College Of Clinical Pharmacy)
권호 표지

Modafinil의 주의력결핍 과잉행동장애 치료효과에 대한 체계적 문헌 고찰

Modafinil for the Treatment of Attention Deficit Hyperactivity Disorder: A Systematic Review

  • 이유정 (숙명여자대학교 임상약학대학원)
  • Lee, Yu-Jeung (Graduate School of Clinical Pharmacy, Sookmyung Women's University)
  • 투고 : 2010.03.17
  • 심사 : 2010.06.04
  • 발행 : 2010.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

주의력결핍 과잉행동장애는 미국에서 약 200만 명의 어린이에게 나타나는 심각한 만성 신경행동학적 장애이다. 주의력결핍 과잉행동장애 치료의 중심은 약물요법이다. 그러나 현재 환자의 약 30%는 주의력결핍 과잉행동장애를 적응증으로 갖도록 허가된 의약품들을 사용해도 적절한 치료효과를 얻지 못하고 있는 상황이다. Modafinil은 methylphenidate나 amphetamines와 같은 각성제와는 다른 약리학적 기전으로 중추신경계를 항진시킨다. 본 연구는 modafinil의 주의력결핍 과잉행동장애 치료효과에 대한 최신 지견을 얻고자, 1990년부터 2010년 3월까지 MEDLINE에 등재된 논문을 ADHD와 Modafinil이라는 MeSH terms로 검색하여 추출한 자료 중에서 대조군이 사용된 무작위 배정 및 이중맹검 임상연구 사례만을 선별하여 임상적 유용성을 평가하였다. 현재 modafinil은 주의력결핍 과잉행동 장애 치료제로 허가된 의약품은 아니지만 최근 여러 국가에서 시행된 연구들은 modafinil이 안전하고 효과적인 주의력결핍 과잉행동장애 치료제일 수 있다는 결과를 보여주고 있다.

키워드

참고문헌

  1. American Academy of Pediatrics. Committee on Quality Improvement, Subcommittee on ADHD. Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics. 2000; 105: 1158-1170. https://doi.org/10.1542/peds.105.5.1158
  2. Birnbaum HG, Kessler RC, Lowe SW. Costs of attention deficit-hyperactivity disorder (ADHD) in the US: excess costs of persons with ADHD and their family members in 2000. Curr Med Res Opin. 2005; 21: 195-206. https://doi.org/10.1185/030079904X20303
  3. Brown RT, Amler RW, Freeman WS, et al., Gender effects on attention-deficit/hyperactivity disorder in adults, revisited. Pediatrics. 2005; 115: e749-e757. https://doi.org/10.1542/peds.2004-2560
  4. Kelsey DK, Sumner CR, Casat CD, et al., Once-daily atomoxetine treatment for children with attention-deficit/ hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebocontrolled trial. Pediatrics. 2004; 114: e1-e8. https://doi.org/10.1542/peds.114.1.e1
  5. Michelson D, Allen AJ, Busner J, et al., Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry. 2002; 159: 1896-1901. https://doi.org/10.1176/appi.ajp.159.11.1896
  6. Biederman J, Spencer T, Wilens T. Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder. Int J Neuropsychopharmacol. 2004; 7: 77-97. https://doi.org/10.1017/S1461145703003973
  7. Taylor FB, Russo J. Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults. J Child Adolesc Psychopharmacol. 2000 ;10: 311-320. https://doi.org/10.1089/cap.2000.10.311
  8. Rugino TA, Samsock TC. Modafinil in children with attention-deficit hyperactivity disorder. Pediatr Neurol. 2003; 29: 136-142. https://doi.org/10.1016/S0887-8994(03)00148-6
  9. Turner DC, Clark L, Dowson J, et al., Modafinil improves cognition and response inhibition in adult attention-deficit/hyperactivity disorder. Biol Psychiatry. 2004; 55: 1031-1040. https://doi.org/10.1016/j.biopsych.2004.02.008
  10. Biederman J, Swanson JM, Wigal SB, et al., Efficacy and safety of modafinil film-coated tablets in children and adolescents with attentiondeficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study. Pediatrics. 2005; 116: e777-e784. https://doi.org/10.1542/peds.2005-0617
  11. Wigal SB, Biederman J, Swanson JM, et al., Efficacy and safety of modafinil film-coated tablets in children and adolescents with or without prior stimulant treatment for attention-deficit/hyperactivity disorder: pooled analysis of 3 randomized, double-blind, placebo-controlled studies. Prim Care Companion J Clin Psychiatry. 2006; 8: 352-360.
  12. Provigil prescribing information. Cephalon, Inc. 2004.
  13. Robertson PJr, Hellriegel ET. Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet. 2003; 42: 123- 137. https://doi.org/10.2165/00003088-200342020-00002
  14. Lin JS, Roussel B, Akaoka H, et al., Role of catecholamines in the modafinil and amphetamine induced wakefulness, a comparative pharmacological study in the cat. Brain Res. 1992; 591: 319-326. https://doi.org/10.1016/0006-8993(92)91713-O
  15. Ferraro L, Antonelli T, O'Connor WT, et al., Modafinil: an antinarcoleptic drug with a different neurochemical profile to d-amphetamine and dopamine uptake blockers. Biol Psychiatry. 1997; 42: 1181-1183. https://doi.org/10.1016/S0006-3223(97)00353-3
  16. Lin J-S, Hou Y, Jouvet M. Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc Natl Acad Sci USA. 1996; 93: 14128-14133. https://doi.org/10.1073/pnas.93.24.14128
  17. Engber TM, Koury EJ, Dennis SA, et al., Differential patterns of regional c-Fos induction in the rat brain by amphetamine and the novel wakefulness-promoting agent modafinil. Neurosci Lett. 1998; 241: 95-98. https://doi.org/10.1016/S0304-3940(97)00962-2
  18. Myrick H, Malcolm R, Taylor B, et al., Modafinil: preclinical, clinical, and post-marketing surveillance--a review of abuse liability issues. Ann Clin Psychiatry. 2004; 16: 101-109. https://doi.org/10.1080/10401230490453743
  19. Amiri S, Mohammadi MR, Mohammadi M, et al., Modafinil as a treatment for Attention-Deficit/Hyperactivity Disorder in children and adolescents: a double blind, randomized clinical trial. Prog Neuropsychopharmacol Biol og Psychiatry. 2008; 32: 145-149. https://doi.org/10.1016/j.pnpbp.2007.07.025
  20. Kahbazi M, Ghoreishi A, Rahiminejad F, et al., A randomized, double-blind and placebo-controlled trial of modafinil in children and adolescents with attention deficit and hyperactivity disorder. Psychiatry Res. 2009; 168: 234-237. https://doi.org/10.1016/j.psychres.2008.06.024